Global X Guru™ Activist ETF
A Post-3Q17 Update on Key Valeant Branded Drugs: Xifaxan, Apriso, and Glumetza
In 3Q17, Valeant’s Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter.
VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016
In 3Q16, Valeant Pharmaceuticals’s (VRX) Gastrointestinal product segment witnessed a drop in revenues due to unfavorable changes in drug pricing.